We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.
- Authors
Nakano, Tadashi; Yoshikawa, Keiji; Kimura, Tairo; Suzumura, Hirotaka; Nanno, Mami; Noro, Takahiko
- Abstract
Purpose: To evaluate the intraocular pressure (IOP)-reducing effects and safety of 0.0015% tafluprost ophthalmic solution (tafluprost) in normal-tension glaucoma (NTG) patients with an IOP of 16 mmHg or less. Methods: NTG patients with a baseline IOP of 16 mmHg or less were enrolled for a one-eye study in which tafluprost was applied once daily for 12 weeks. The presence of adverse drug reactions and the cumulative incidence of adverse events were also investigated. Results: Among the 44 enrolled patients, 41/44 (93.2%) eyes completed the study. The baseline IOP was 13.2 ± 1.3 mmHg in the study eyes and 13.0 ± 1.3 mmHg in the fellow eyes, which was not statistically significant ( P = 0.9173, Student's t test). The values obtained for IOP in the study eyes versus fellow eyes were 10.2 ± 1.6 versus 12.1 ± 1.5 mmHg at week 12. The IOP difference between the study eyes and the fellow eyes was statistically significant ( P < 0.0001, Student's t test). The cumulative incidence of adverse events was 58.5% by week 12. Ocular itching was the most frequently observed adverse event (29.3%). All adverse events were clinically tolerable. Conclusions: Tafluprost induced significant IOP reductions in NTG patients with a baseline IOP of 16 mmHg or less without raising any safety concerns.
- Subjects
GLAUCOMA; EYE diseases; INTRAOCULAR pressure; DRUG side effects; THERAPEUTICS
- Publication
Japanese Journal of Ophthalmology, 2011, Vol 55, Issue 6, p605
- ISSN
0021-5155
- Publication type
Article
- DOI
10.1007/s10384-011-0082-7